Angelini buys rare-disease focused Catalyst for $4.1B

Andrew Joseph covers well being, drugs, and the biopharma business in Europe. You may attain Andrew on Sign at drewqjoseph.71.

The Italian firm Angelini Pharma mentioned Thursday it will purchase the rare-disease targeted Catalyst Prescription drugs for roughly $4.1 billion in money. 

The deal values Florida-based Catalyst at $31.50 a share, a 28% premium to the 30-day interval earlier than April 22, when it turned publicly identified {that a} deal was within the works. 

Shopping for Catalyst, which sells three accepted medicines, will give Angelini a foothold within the U.S. market. It additionally builds on its work in neurology.